2070P - Assessment of healthy lifestyle habits in breast cancer patients

Background

Healthy lifestyle habits such as avoiding overweight, engaging in moderate physical activity for at least 150 minutes per week, and getting good quality sleep have not only been shown to decrease the incidence of certain cancers, but also have a clear impact on the outcome of patients diagnosed with breast cancer. Adherence to these recommendations has an impact on quality of life, and some studies suggest their beneficial effect on patient survival.

Methods

We included 181 patients diagnosed with breast cancer in different stages, Multivariable ambulatory circadian monitoring of skin temperature, motor activity, light exposure, and sleep patterns was performed for 7 consecutive days through a small watch-like device called Kronowise 3.0. The patients are divided into 3 groups: group 1 includes metastatic patients, group 2 consists of patients with early-stage breast cancer undergoing chemotherapy, and group 3 comprises patients with early-stage breast cancer under follow-up (more than 1 year after the completion of chemotherapy).

Results

The table describes the mean age with standard deviation, physical activity categorized as patients who achieve ≥ 150 minutes of moderate physical activity (MPA) per week, ≥ 300 minutes of moderate physical activity per week, ≥ 75 minutes of vigorous physical activity per week, patients with good sleep hygiene (between 7 and 9 hours of sleep per day), patients with < 10 hours of sedentary behavior, and the percentage of patients with overweight and obesity in each group. Table: 2070P

Conclusions

Despite breast cancer patients not being sedentary and having higher levels of moderate physical activity compared to the general population, the occurrence of vigorous physical activity is quite low among these patients. It is imperative to establish proper sleep hygiene in these patients in order to improve parameters and reduce the rates of overweight and obesity, particularly among the metastatic population and long-term survivors, where these rates are significantly higher.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

This abstract is part of the CLARIFY project that has received funding from the European Union’s Horizon 2020 Research and Innovation Programme under grant agreement No. 875160.

Disclosure

All authors have declared no conflicts of interest.